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Abstract: Constitutive activation of extracellular signal regulated kinase (ERK)-Jun NH2-terminal kinase (JNK) signaling commonly occurs in tumors. The activation of ERK promotes cell proliferation, whereas that of JNK induces cell
apoptosis. However, the apoptotic mechanism of ERK-JNK signaling in cancer is not well understood. Recently, we
identified that apoptosis and activation of the JNK signaling pathway were induced after cordycepin treatment in human renal cancer, suggesting that JNK signaling might contribute to TK-10 cell apoptosis. We investigated the apoptotic effects of cordycepin by evaluating the activation of the ERK-JNK signaling pathway in renal cancer TK-10 cells.
We found that cordycepin downregulated ERK and DUSP5, upregulated phosphorylated-JNK (p-JNK), and induced
apoptosis. Moreover, we showed that siRNA-mediated inhibition of ERK downregulated DUSP5, whereas ERK overexpression upregulated DUSP5, and that DUSP5 knockdown by siRNA upregulated p-JNK. The JNK-specific inhibitor
SP600125 upregulated nuclear translocation of β-catenin, and downregulated Dickkopf-1 (Dkk1), which has been
shown to be a potent inhibitor of Wnt signaling. Dkk1 knockdown by siRNA upregulated nuclear β-catenin, suggesting the involvement of the Wnt/β-catenin signaling pathway. DUSP5 overexpression in TK-10 cells decreased p-JNK
and increased nuclear β-catenin. The decreased Bax activation markedly protected against cordycepin-induced
apoptosis. Bax subfamily proteins induced apoptosis through caspase-3. Taken together, we show that JNK signaling activation by cordycepin mediated ERK inhibition, which might have induced Bax translocation and caspase-3
activation via regulation of DUSP5 in TK-10 cells, thereby promoting the apoptosis of TK-10 cells. Targeting ERK-JNK
signaling via the apoptotic effects of cordycepin could be a potential therapeutic strategy to treat renal cancer.
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Introduction
Cordycepin has been reported to have numerous biological activities, including antiproliferative [1, 2], apoptotic [3-5], inhibition of platelet
aggregation [6], inhibition of cell migration and
invasiveness, and anti-inflammatory activities.
In mice, cordycepin can reduce tumor formation in a model of metastasis and has therefore
been proposed as an anticancer drug [7].
Cordycepin induces cell apoptosis through
three signaling pathways: the PKA/TdT signaling pathway, caspase signaling pathway, and

p38/JNK signaling pathway. The caspase signaling pathway is the most prominent pathway
by which cell apoptosis is induced by cordycepin. Following cordycepin binding to DR3 receptor, DR3 activates caspase-8 via Fas-associated
protein with death domain (FADD). Subsequently,
caspase-8 may directly activate caspase-3 or
induce mitochondria to release cytochrome c,
which also activates caspase-3 with the help of
Apaf1 and caspase-9 [8-10].
The extracellular signal-regulated kinase 1/2
(ERK1/2) cascade is a central signaling path-
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way that regulates a wide variety of cellular processes, including mainly proliferation, differentiation, transformation, and survival, but apoptosis and stress response as well. ERK1 and
ERK2 isoforms are both phosphorylated at the
conserved T-X-Y motif in the activation loop of
the kinase. Generally, the ERK signaling is activated by growth factors and plays a role in cell
proliferation [11]. Conversely, the JNK signaling
pathway is stimulated by genotoxic agents and
cytokines mediating growth arrest and apoptosis [12-16], indicating that more complex roles
of these mitogen activated protein kinase
(MAPK) pathways exist to transmit other ultimately distinct cellular effects in various subcellular organelles [17, 18].
ERK is negatively regulated by specific protein
phosphatases. Dual-specificity MAPK phosphatases (DUSPs) are a form of phosphatase that
can act on tyrosine or serine/threonine residues. Among them, DUSP5 and DUSP6, localized in the nucleus [19] and cytoplasm, respectively [20], specifically dephosphorylate ERK
[21]. These phosphatases belong to the large
family of DUSPs, since they dephosphorylate
both tyrosine and serine/threonine residues
[22]. Since DUSP5 possesses a functional
nuclear localization signal and has been proposed to act as a nuclear anchor for ERK, its
substrate selectivity is only determined by the
specific interaction with nuclear ERK [23]. ERK
signaling is required for the induction of DUSP5
and DUSP6 [24-27], which are involved in a
negative feedback loop that tightly controls the
levels of phosphorylated ERK (p-ERK). The role
of DUSPs in both cancer progression and cancer resistance is obvious, making them rational
targets for new therapeutics [24]. DUSP5 negatively regulates members of the MAPK superfamily (MAPK/ERK, SAPK/JNK, p38), which are
associated with cellular proliferation and differentiation. In this study, we analyzed the effects
of cordycepin on renal cancer cell apoptosis
and studied the relationship between ERK and
JNK. We attempted to identify the apoptotic
pathway by which cordycepin-mediated inhibition of ERK promoted JNK signaling by regulating DUSP5, resulting in inhibition of nuclear
β-catenin translocation, thus inducing apoptosis in human renal-cancer cells. The data presented herein clearly show that cordycepin is
involved in the ERK-JNK signaling pathway by
modulating DUSP5 signaling, and that the consequent activation of the Bax/caspase-3-mediated pathway causes cancer cell death.
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Materials and methods
Cell lines and cell viability assay
The human renal adenocarcinoma cell line
TK-10 was obtained from the National Cancer
Center (Ilsan, Korea). The cells were grown in
RPMI1640 medium supplemented with 10%
(v/v) FBS and 1% (w/v) penicillin-streptomycin
at 37°C under 5% (v/v) CO2. Cells (5 × 103/well)
were seeded into a 96-well plate. After 24-h
incubation, the cells were treated with 0, 20,
40, 60, 80, 100, and 120 μM cordycepin for 48
h. Cell viability assays were conducted as
reported previously [28]. At the end of the treatment, 10 μl of CCK-8 solution was added to the
cell solution and incubated at 37°C for 1 h. Cell
viability was determined by measuring the absorbance at 450 nm using a microplate reader
(Sunrise, Tecan, Switzerland). The assays were
performed in triplicate. The appropriate dose
was determined by evaluating the cytotoxicity
of cordycepin after 48 h.
Reagents and chemicals
Fetal bovine serum (FBS), 1% (w/v) penicillinstreptomycin stock solution, phosphate-buffered saline (PBS), and Roswell Park Memorial
Institute (RPMI) 1640 medium were obtained
from Thermo (Paisley, Scotland, UK). Cordycepin
(3’-deoxyadenosine, from Cordyceps militaris)
was purchased from Sigma-Aldrich (St. Louis,
MO, USA, C3394). An Annexin-V-FLUOS staining
kit was purchased from Roche Diagnostics
GmbH (Mannheim, Germany). Whole cell lysis
buffer was purchased from Intron (Seoul,
Korea), and transfection reagent Hilymax and
cell-counting kit-8 (CCK-8) from Dojindo (Dojindo, Japan). DAPI (4’,6-Diamidino-2-Phenylindole,
Dihydrochloride) and TRIZOL reagent were purchased from Thermo. Antibodies against
β-catenin, p-JNK, caspase-3, p-Akt, and β-actin
were purchased from Cell Signaling (Beverly,
MA, USA). Antibodies against ERK, JNK, Akt,
DUSP5, Dkk1, and Bax, and the JNK inhibitor
SP600125 were from Santa Cruz (Dallas, TX,
USA).
Cell cycle analysis by propidium iodide (PI)Annexin V staining
To detect the effect of cordycepin on apoptosis,
we analyzed the PI-Annexin V staining pattern
by using the Annexin V-FLUOS staining kit
(Roche Diagnostics). Cells were treated with 0,
Am J Cancer Res 2016;6(8):1758-1771
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20, 40, 60, 80, and 100 μM of cordycepin for
48 h, collected, and washed twice with PBS.
The cell suspension was centrifuged at 2000 ×
g for 2 min and incubated at 24°C with 0.2 mg/
mL Annexin V FLUOS and 1.4 mg/mL PI and
RNase solution for 15 min under dark conditions. Measurements were conducted using
an Image Cytometer (NUCLEOCOUNTER® NC3000TM; Chemometec, Copenhagen, Denmark)
with an excitation wavelength of 488 nm and a
530/30-nm band-pass filter to detect Annexin
V and a 670 nm high-pass filter to detect PI.
Microarray analysis
Total RNA was extracted from vehicle- or 100
µM cordycepin-treated TK-10 renal call adenocarcinima. The total RNA from each sample
was extracted using TRIZOL reagent according
to the manufacturer’s instructions. For microarray analysis of the cordycepin-treated renal
cancer cells, the Human Twin ChipTM Human 44
K (Genocheck, Seoul, Korea) was used for the
transcription profiling analysis. In brief, the Cy3(vehicle) and Cy5-labeled (cordycepin-treated)
cRNAs were hybridized with the Human 44 K
microarray, and the hybridization images were
analyzed with an Agilent DNA Microarray
Scanner. All data normalization and selection
of up-regulated and down-regulated genes
were performed using GeneSpring GX 7.3
(Agilent Technology). The microarray data have
been submitted to the Gene Expression
Omnibus database (GEO accession number:
GSE81718).

DUSP5 (Lenti H1.4-ERK1, DUSP5/RFP; Bioneer
Corp., Daejeon, Korea). Small interfering RNAs
(siRNAs) were purchased from Cell signaling
and ST Pharm (Seoul, Korea). ERK1/2 siRNA
was purchased from Cell signaling (SignalSilence® p44/42 MAPK (Erk1/2) siRNA #6560).
The nucleotide sequences of the siRNAs used
in this study were as follows: for DUSP5, 5’-GGC
CUU CGA UUA CAU CAA G-3’; for β-catenin,
5’-GCU UGG AAU GAG ACU GCU GAU-3’ and for
Dkk1 siRNA, 5’-AAG AAC GGA AGU GUG AUA
UGU-3’. Scrambled control siRNA (Silencer
Negative Control 5) was provided by Ambion
(Waltham, MA, USA). Lentiviral infection was
performed according to the manufacturer’s
method. Briefly, TK-10 cells were seeded (2 ×
105 cells/well) into a 6-well plate and infected
with 1 mL of lentivirus for 8 h. After incubation,
the cells were supplied with growth medium
containing 10% FBS and were harvested 48 h
later for further assays. Transfection of siRNA
into the TK-10 cells was performed using
Lipofectamine RNAiMAX reagent (Invitrogen,
Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. Cells were then treated with 100 mM cordycepin for 48 h.
Fractionation and protein extraction

To study the biological functions of the regulated genes through their interaction network, we
conducted a network analysis by using ingenuity pathway analysis (IPA, http://www.ingenuity.
com) to examine the biological functions of the
differentially regulated genes and proteins
according to ontology-related interaction networks, including apoptosis signaling. Network
generation was optimized from the obtained
expression profiles when possible and was
aimed at producing highly connected networks.

TK-10 cells were incubated with cordycepin for
2 days. The cells were collected with 2 mL of
homogenization buffer A (25 mM Tris (pH 7.5), 2
mM EDTA, 0.5 mM EGTA, 1 mM DTT, protease
inhibitor cocktail, 1 mM PMSF, and 0.02% Triton
X-100) per culture dish, homogenized 15 times
using a 15-mL Dounce homogenizer with pestle A, and centrifuged at 100,000 × g for 30
min. The supernatant cytosolic fraction was
transferred to a new tube and 500 μL of homogenization buffer B (homogenization buffer A
containing 1% Triton X-100) was added to the
pellet. The pellet was resuspended by sonication, incubated for 30 min at 4°C by shaking,
and centrifuged at 100,000 × g for 30 min. The
supernatant nuclear fraction was transferred to
a fresh tube. The protein contents of the cytosolic and nuclear fractions were determined by
using a bicinchoninic acid (BCA) assay kit
(Thermo Scientific, Rockford, IL, USA) and analyzed by western blotting using anti-β-catenin
antibody.

Gene overexpression and silencing

Western blotting

For overexpression of ERK, we used lentivirus
carrying RFP-conjugated full-length ERK1 and

Cell lysates were mixed with loading buffer and
separated by SDS-PAGE. Proteins were then

Gene ontology-based network analysis
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Figure 1. Cordycepin induces apoptosis in renal cancer cells. A: Inhibition
of the growth of renal cancer cells by
cordycepin. TK-10 cells were exposed
to cordycepin at 0, 20, 40, 60, 80, 100,
or 120 μM for 48 h. Data are presented as the mean ± standard deviation
from triplicate experiments. *P<0.05,
**P<0.01, and ***P<0.001 vs. untreated control. B: Apoptosis analysis
of TK-10 cells exposed to cordycepin.
The cells were treated with cordycepin
at 0, 20, 40, 60, 80, or 100 μM for
48 h. The cells were doubly strained
with PI and Annexin V and analyzed
by flow cytometry. The data are representative of three independent experiments.

transferred to nitrocellulose membranes. Nonspecific binding sites on the membranes were
blocked using 5% non-fat dry milk for 90 min
at room temperature. Membranes were incubated with primary antibodies against ERK
(1:1000), JNK (1:200), p-JNK (1:200), β-catenin
(1:500), p-β-catenine (1:100), caspase-3
(1:500), Bax (1:1000), Akt (1:1000), p-Akt
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(1:1000), DUSP5 (1:1000), Dkk1 (1:1000), and
β-actin (1:2000) at 4°C overnight, followed by
secondary antibodies for 1 h at room temperature. Protein bands on the membranes were
visualized using an ECL Plus Blotting Detection
System from Santa Cruz Biotechnology Inc. and
ChemiDoc MP system (Bio-Rad, Hercules, CA,
USA). Densitometric measurements of bands
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were made using the ImageJ software. The
expression levels of proteins were quantitatively analyzed through comparison with actin as
an internal control.
Immunofluorescence microscopy
Untreated control and over-DUSP5 transfected
TK-10 cells were seeded at a density of 4 × 104
cells/well on a coverslip in a 12-well plate. The
cells were pretreated with cordycepin at 100
mM for 48 h. The cells were washed twice with
250 μM (1 ×) PBS (pH 7.5) and fixed with 4%
(v/v) formaldehyde for 15 min. They were permeabilized with 0.1% (v/v) Triton X-100 for 15
min and then incubated with 3% (w/v) bovine
serum albumin (BSA) for 1 h to prevent nonspecific binding. The cells were incubated with
β-catenin monoclonal purified mouse IgG1 as a
primary antibody (diluted to 1:100 in 3% (w/v)
BSA) overnight at 4°C followed by 1-h incubation in the dark with fluorescein isothiocyanateanti-mouse antibody (diluted to 1:200 in 3%
(w/v) BSA; Invitrogen Life Technologies, Carlsbad, CA, USA) as a secondary antibody. Fixed
cells were washed with PBS and stained with
4,6-diamidino-2-phenylindole (DAPI) at room
temperature. The cells were again washed
twice with PBS and mounted with mounting
solution for observation. Images were acquired
using an LSM 710 laser-scanning confocal
microscope (Carl Zeiss, Jena, Germany) equipped with a C-Apochromat 40 ×/1.2 water
immersion lens (488 nm Ar laser/505-550 nm
detection range). Image data were analyzed
with the ZEN 2009 Light Edition software (Carl
Zeiss).
Statistical analysis
GraphPad Prism software (GraphPad, San
Diego, CA, USA) was used for the statistical
analyses. Student’s t-test was used to assess
differences between the control and the cordycepin-treated groups. P-values less than 0.05
were considered statistically significant
Results
Cordycepin inhibits lung cancer cell growth
To investigate the effects of cordycepin on
renal cancer cell proliferation, TK-10 cells were
treated directly with 0, 10, 20, 40, 60, 80, 100,
or 120 μM cordycepin for 48 h. As shown in
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Figure 1A, cordycepin inhibited the growth of
the cells during the 48-h incubation period in a
dose-dependent manner. At 100 μM, cordycepin inhibited approximately half of the TK-10
cell population. Thus, the half-maximal inhibitory concentration (IC50) was determined as
100 μM (Figure 1A). The apoptotic effect of
cordycepin on TK-10 renal cancer cells was
analyzed with Annexin V- and PI-staining using
flow cytometry after 48-h treatment with 0 to
100 μM cordycepin. The relative proportion of
non-viable cells was quantitatively measured
as cells at the early stage of apoptosis (Annexin
V-stained, non-disrupted cells) or as cells entering the late stage of apoptosis (disrupted or
lysed cells). In 20 to 40 μM cordycepin-treated
cells, no drastic change in the Annexin V-stained
viable fraction was observed (91% to 89% and
88%) (Figure 1B). However, in cells treated with
100 μM cordycepin, a marked shift from the
normal state to the early apoptotic stage (4% to
26%), was observed whereas the viable fraction decreased from 91% to 65%. Thus, cordycepin at 100 μM induces apoptosis in renal
cancer cells.
Cordycepin alters gene expression
To identify the potential genes involved in the
anti-cancer activity of cordycepin, we conducted microarray analysis of TK-10 cancer cells
after treatment with 100 μM cordycepin.
Among the 43,142 unique genes tested,
30,165 genes were expressed in the cordycepin-treated cells. Among these 30,165 genes,
2,243 and 1,442 genes were up- and downregulated, respectively, after 48-h treatment with
cordycepin. Genes that were significantly up- or
downregulated by more than 2-fold were subjected to GO enrichment analysis using the
Database for Annotation, Visualization, and
Integrated Discovery (DAVID) tools (http://
david.abcc.ncifcrf.gov/). The upregulated genes were mainly involved in developmental process, positive regulation of apoptosis, immunity and defense, central nervous system development, sensory perception, endocytosis, cell
cycle control, and negative regulation of cell
development (Figure 2A). The downregulated
genes were related to intracellular signaling
cascade, apoptosis, regulation of cellular protein, and cell adhesion-mediated signaling. To
identify genes potentially involved in apoptosis
among the cordycepin-induced genes, we used
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Figure 2. Gene expression analysis and signal network of apoptotic genes. A: Results of microarray analysis of gene
expression in response to 100 μM cordycepin for 48 h. B: Venn diagram of expression of genes that were altered
more than 2-fold and apoptosis-related genes in response to cordycepin. C: List of apoptosis-related genes that
were altered more than 2-fold in response to cordycepin. D: Signal network of the apoptotic genes generated using
a Qiagen IPA (red: upregulated genes, green: downregulated genes).

the GeneCards database (http://www.genecards.org/) (Figure 2B, 2C). Quantitative alterations in gene expression were observed in
cordycepin-treated renal cancer cells as compared to that in control cells. The signal network of apoptotic genes regulated in response
to cordycepin is shown in Figure 2D. Among
these, DUSP5 and ERK1 were identified as central hubs of the apoptosis-related interactome
network in the cordycepin-treated lung cancer
cells.
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Cordycepin downregulates p-ERK and DUSP5
and upregulates p-JNK and Bax
Because the expression of p-ERK decreases
after cordycepin treatment, we examined the
cell signaling modulated by ERK in TK-10 cells
treated with cordycepin. The expression of
p-ERK (active ERK), DUSP5, p-JNK (active JNK),
and total JNK at 24 and 48 h after cordycepin
treatment was analyzed using western blot
analysis (Figure 3A). The expression of total
Am J Cancer Res 2016;6(8):1758-1771
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Figure 3. Expression of p-ERK, ERK, DUSP5, p-JNK, JNK, and Bax proteins after cordycepin treatment. A: Western
blots showing expression of p-ERK, ERK, DUSP5, p-JNK, and JNK at 0, 24, and 48 h in TK-10 cells after cordycepin
treatment. B: Western blots showing expression of Bax, caspase-3, and cleaved caspase-3 at 0, 24, and 48 h in
TK-10 cells after cordycepin treatment. Bar graphs represent densitometric analysis of at least three separate experiments (means ± SD). *P<0.05, **P<0.01, and ***P<0.001.

JNK protein was not obviously altered at different time points when compared to the control
(0 h). However, p-ERK and DUSP5 protein
expression decreased after cordycepin treatment in a time-dependent manner. A 2-fold
increase in p-JNK expression was observed at
48 h after cordycepin treatment as compared
with the control. The cell lysates were probed
with various antibodies to examine the cordycepin-induced apoptotic cell signaling. Western
blot analysis showed that Bax, caspase-3, and
cleaved caspase-3 expression increased after
cordycepin treatment.
Cordycepin-mediated ERK inhibition results
in JNK phosphorylation and β-catenin nuclear
translocation
We assessed whether ERK was involved in the
negative regulation of p-JNK after cordycepin
treatment by siRNA-mediated silencing of ERK.
Cordycepin decreased the expression of ERK
and increased that of p-JNK, whereas siRNAmediated inhibition of ERK effectively lowered
the DUSP5 protein level and abrogated p-JNK
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expression, indicating that ERK-DUSP5 signaling is involved in the regulation of JNK phosphorylation (Figure 4A). To confirm whether
JNK is involved in β-catenin regulation after
cordycepin treatment, we used SP600125, a
highly specific JNK inhibitor, which blocks JNK
phosphorylation by binding to its ATP-binding
site. In TK-10 cells treated with 10 mM
SP600125, the level of phosphorylated JNK
increased at 48 h after cordycepin treatment
as compared to the controls (Figure 4B), which
indicated that cordycepin induced the upregulation of JNK activity. Next, we investigated
whether SP600125 affected the nuclear translocation of β-catenin. We found that SP600125
treatment significantly increased the nuclear
translocation of β-catenin at 48 h after cordycepin treatment as compared to the control
(Figure 4B). However, cytosol β-catenin was
markedly decreased at 48 h by SP600125
treatment. We then examined the expression
of DUSP5 and JNK. Cordycepin increased the
level of Bax protein (Figure 4B). These results
suggest that the downregulation of ERK and
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Figure 4. Cordycepin-mediated ERK inhibition downregulates DUSP5 and phosphorylates JNK. A: Representative
western blots of TK-10 cells treated with cordycepin showing the expression of p-ERK, ERK, DUSP5, p-JNK, JNK. TK10 cells were incubated with siRNA directed against ERK (si-ERK) or negative control siRNA for 48 h, and transfected
with an ERK-overexpressing construct for 48 h. B: Cordycepin-mediated DUSP5 inhibition phosphorylates JNK and
increases Bax. TK-10 cells were incubated with siRNA directed against DUSP5 (si-DUSP5) for 48 h, and transfected
with a DUSP5-overexpressing construct for 48 h. TK-10 cells were treated with cordycepin or cordycepin and 10 mM
SP600125 for 48 h. Bar graphs represent densitometric analysis of at least three separate experiments (means ±
SD). *P<0.05, **P<0.01, and ***P<0.001.

DUSP5 contributes to the expression of Bax
after cordycepin treatment. We next performed
a loss-of-function analysis using DUSP5 knockdown by siRNA. si-DUSP5 enhanced p-JNK
expression, whereas DUSP5 overexpression
suppressed the p-JNK protein-mediated increase in Bax (Figure 4B). Taken together, these
results indicate that cordycepin-mediated ERK
inhibition downregulates DUSP5, which phosphorylates JNK and regulates β-catenin nuclear
translocation. In addition, si-β-catenin significantly downregulated nuclear β-catenin and
upregulated Bax, whereas SP600125 significantly upregulated nuclear β-catenin and downregulated Bax (Figure 5A, 5B), indicating that
β-catenin signaling promotes apoptosis by
upregulating Bax in TK-10 cells. Taken together,
1765

these results indicate that cordycepin-induced
DUSP5 downregulation upregulated the p-JNKinduced decrease in nuclear β-catenin translocation, leading to the upregulation of Bax.
DUSP5-JNK signaling regulates nuclear
β-catenin translocation signaling through Dkk1
expression
We next examined the potential role of JNK in
the regulation of β-catenin signaling in TK-10
cells. As shown in Figure 6A, Dkk1 was downregulated in JNK inhibitor SP600125-treated
TK-10 cells and siRNA-mediated inhibition of
Dkk1 upregulated the levels of nuclear β-catenin protein and phosphorylated protein kinase
B (p-Akt) after cordycepin treatment (Figure
Am J Cancer Res 2016;6(8):1758-1771
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Figure 5. Cordycepin upregulates p-JNK to prevent nuclear β-catenin translocation. A: TK-10 cells were treated with cordycepin or cordycepin and 10 mM SP600125
for 48 h. TK-10 cells were incubated with siRNA directed
against β-catenin (si-β-catenin) or negative control siRNA for 48 h. B: Band intensities are represented as percentage of p-JNK, nuclear β-catenin. Data were densitometric analysis of at least three separate experiments
(means ± SD). *P<0.05, **P<0.01, and ***P<0.001.

6B). These findings indicate that JNK regulates nuclear β-catenin translocation signaling
through Dkk1 expression. There is a crosstalk
between the pro-apoptotic JNK pathway and
the pro-survival Akt pathway at multiple levels.
To further investigate whether the regulation of
β-catenin by JNK after cordycepin treatment is
related to Akt, we examined the expression of
p-Akt and Akt protein after cordycepin treatment by western blotting. Additionally, we
silenced β-catenin using specific siRNA and
blocked JNK activation with SP600125. We
found that p-Akt was upregulated and total Akt
was not affected at 48 h in the SP600125treated TK-10 cells as compared to that in the
untreated control (Figure 6B), suggesting that
JNK is dependent on Akt in this study.
Cordycepin enhanced p-JNK (Figure 6A). We
next performed a loss-of-function analysis
using DUSP5 knockdown by siRNA. si-DUSP5
enhanced p-JNK, and the selective JNK inhibitor SP600125 blocked JNK, whereas DUSP5
overexpression suppressed the p-JNK proteinmediated increase in Bax (Figure 6B). Consistent with this finding, β-catenin nuclear
translocation was inhibited after cordycepin
treatment, whereas both cytosolic and nuclear
β-catenin increased in untreated control as
confirmed by confocal microscopy (Figure 6C).
DUSP5 over-expressing constructs were trans-
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fected into TK-10 cells, which were then treated
with cordycepin for 24 h; this upregulated
nuclear β-catenin translocation and JNK mediated Dkk1, and DUSP5 overexpression enhanced the nuclear translocation of β-catenin
(Figure 6C) and markedly protected against
cordycepin-induced apoptosis (Figure 6D).
Discussion
Cordycepin has been reported to have various
biological activities, including inhibition of protein synthesis and cell adhesion, inflammation,
platelet aggregation, and mRNA polyadenylation [29-31]. In addition, it has remarkable
anticancer potential, such as inhibition of cell
proliferation [32, 33], induction of apoptosis,
and inhibition of cell growth, migration and
invasiveness [34, 35]. These inhibitory effects
on tumor have been observed in oral, lung,
prostate, and colorectal carcinoma, and mainly
involve the induction of apoptosis via the targeting of specific molecules and pathways [3639]. However, the roles of ERK and JNK signaling in the induction of apoptosis are not clearly
understood. This study showed that treatment
with 100 μM cordycepin reduced viability and
strongly inhibited the growth of renal cancer
TK-10 cells (Figure 1A). Moreover, 100 μM
cordycepin had an effect on the morphology of
TK-10 cells as compared to the untreated con-
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Figure 6. DKK1 signaling through JNK attenuates p-Akt, resulting in inhibition of nuclear β-catenin translocation. A:
Cordycepin-mediated p-JNK upregulation enhances Dkk1. TK-10 cells were treated with cordycepin or cordycepin
and 10 mM SP600125 for 48 h. TK-10 cells were incubated with siRNA directed against DUSP5 (si-DUSP5) or negative control siRNA for 48 h. B: TK-10 cells were incubated with siRNA directed against Dkk1 (si-Dkk1) or negative
control siRNA for 48 h, and transfected with a DUSP5-overexpressing construct for 48 h. Bar graphs represent densitometric analysis of at least three separate experiments (means ± SD). *P<0.05, **P<0.01, and ***P<0.001. C:
TK-10 cells were grown on glass coverslips and treated with cordycepin or cordycepin with DUSP5 overexpression
for 48 h. Samples were analyzed by indirect immunofluorescence with confocal microscopy. The cellular localization
of β-catenin (cytosol, green; nucleus, blue) is shown in the middle panels. The right panels are merged images. The
bar indicates 20 μm. D: Analysis of apoptotic protection by DUSP5 overexpression using double-labeled flow cytometry in TK-10 cells treated with cordycepin. Control (left panel) and DUSP5 over-expressing (right panel) constructs
were transfected into TK-10 cells, which were then treated with cordycepin for 24 h.
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trol and 20-80 μM cordycepin (Figure 1B, 1C).
The results of Annexin V/PI staining using FACS
demonstrated that cordycepin could induce
pro-apoptosis. Cordycepin at 100 μM induced
the transformation of cells from the normal
state (untreated group: 91.0% normal, 4.0%
early apoptotic, and 3% late apoptotic) to the
apoptotic state (65.0% normal, 26.0% early
apoptotic, and 8.0% late apoptotic) (Figure 1D).
These results suggest that cordycepin exhibits
anti-lung cancer activity by promoting proapoptosis.
To analyze cordycepin-related gene expression
in renal cancer cells, we used a cDNA microarray approach. Clustering of the microarray data
identified groups of genes that were differentially regulated upon treatment of TK-10 cells
with 100 μM cordycepin. The GO categories of
genes whose expression was altered by at least
2-fold are shown in Figure 2A. Among these, 20
genes whose expression increased and 9 with
decreased expression were related to apoptosis (Figure 2B, 2C). To explore the major cordycepin-regulated proteins identified using GO
analysis, we used IPA to query 29 proteins that
were up- or downregulated by cordycepin, yielding a distinct interconnected network of 33 proteins (Figure 2D). Among these, ERK/JNK
(MAPK8) were the center of the apoptosis-related protein network. In present study, we
showed that the ERK/DUSP5/JNK pathway was
involved in TK-10 cell apoptosis after cordycepin treatment. First, we found that cordycepinmediated ERK inhibition upregulated p-JNK and
the reduction of nuclear β-catenin preceded
TK-10 renal cancer cell apoptosis, suggesting
that JNK phosphorylation and nuclear β-catenin
were involved in mediating cordycepin-induced
TK-10 cell apoptosis. Second, cordycepin upregulated JNK phosphorylation through ERKmediated DUSP5 regulation. Third, treatment
with the JNK inhibitor SP600125 significantly
increased nuclear β-catenin levels, leading to a
decrease in the protein levels of Bax and
cleaved caspase-3. Finally, siRNA-mediated
inhibition of β-catenin attenuated Bax levels
after cordycepin treatment. Previous studies
on the expression and function of the ERK and
JNK signaling pathways in cancer have shown
controversial results, indicating that the physiological role of ERK varies according to the cancer type. ERK increases the level of c-Jun
expression by affecting its transcription and
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stability [40] whereas ERK inhibition increased
JNK activity [41]. We found that ERK decreased,
whereas p-JNK increased at 24 h and 48 h
after cordycepin treatment (Figure 3A). JNK
plays a pivotal role in death receptor-initiated
extrinsic as well as mitochondrial intrinsic
apoptotic pathways [42]. After phosphorylation,
JNK can activate its downstream transcriptional factors, inducing cell apoptosis by triggering
the expression of the pro-apoptotic target gene
Bax [43].
Thus, our results suggest that cordycepinmediated p-JNK upregulation by downregulating ERK induces TK-10 cell apoptosis. Because
DUSP5 is an inducible, nuclear, dual-specificity
phosphatase, which specifically interacts with
and inactivates the ERK1/2 MAP kinases in
mammalian cells [25], we assessed whether
DUSP5 was affected at 24 h and 48 h after
cordycepin treatment. DUSP5 levels decreased
at both time points (Figure 3A). We found that
phosphorylation of ERK reduced along with the
upregulation in the expression of p-JNK at 24 h
and 48 h after cordycepin treatment (Figure
3B). This suggests that cordycepin-mediated
ERK inhibition promotes p-JNK, inducing the
expression of the pro-apoptotic proteins Bax
and cleaved caspase-3, leading to TK10 cell
apoptosis after cordycepin treatment.
These findings are consistent with those of previous studies [44, 45]. The JNK specific inhibitor SP600125 significantly suppressed cordycepin-induced Bax (Figure 4B), strongly indicating that JNK regulates the activity of Bax in
TK-10 cells. Next, we investigated whether ERK
was involved in the negative regulation of p-JNK
after cordycepin treatment (Figure 5A). We
found that ERK overexpression decreased the
expression of p-JNK, whereas siRNA-mediated
inhibition of ERK increased p-JNK, indicating
that ERK indeed mediated JNK dephosphorylation. ERK-silenced TK-10 cells treated with
cordycepin also showed decreased DUSP5 and
increased p-JNK levels (Figure 4A), while siRNA-mediated inhibition of DUSP5 increased
p-JNK levels (Figure 4B). These findings indicated that cordycepin-mediated ERK inhibition
upregulated p-JNK through decreased function
of the JNK inhibitor DUSP5, inducing TK-10 cell
apoptosis. The mechanism by which JNK regulates β-catenin in an Akt-dependent manner
after cordycepin is not clear. JNK-regulated
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phosphatase activities may be involved in the
nuclear translocation of β-catenin [46]. We
investigated whether SP600125 affected
nuclear β-catenin accumulation. We found that
JNK inhibition by SP600125 increased the
nuclear translocation of β-catenin at 48 h after
cordycepin treatment, suppressing β-catenin
cytosol translocation (Figure 4B). The transcription factor β-catenin can downregulate Bax
gene expression and prevents caspase-dependent apoptosis [47]. In addition, the direct
effect of JNK on Bax and consequent Bax translocation to mitochondria are essential to initiating mitochondrial apoptosis [48]. We further
studied whether the inhibition of β-catenin by
siRNA could enhance the expression of Bax
(Figure 5A, 5B). We found that the inhibition of
β-catenin by siRNA increased the expression of
Bax, indicating that it also significantly induces
TK-10 cell apoptosis after cordycepin treatment. Because β-catenin/Wnt signaling activates Akt, which phosphorylates and inhibits
Bax [49], the effect of Akt inactivation on Bax
activation was elucidated using phosphatidylinositol 3 kinase (PI3K) inhibitor, LY-294002,
an agent that attenuates PI3K-mediated Akt
activation [50]. Our results demonstrated that
Dkk1, a negative regulator of Wnt signaling,
affected β-catenin expression, which in turn
affected Akt activation in TK-10 cells after
cordycepin treatment (Figure 6B). Nuclear
β-catenin translocation decreased after cordycepin treatment, but recovered in si-Dkk1transfected cells after cordycepin treatment.
siRNA-mediated Dkk1 inhibition also activated
Akt (Figure 6B). The results of the present study
suggest that the inhibition of p-JNK-mediated
β-catenin/Wnt signaling downregulates Akt
activation, a kinase that phosphorylates and
upregulates Bax, and that ERK regulated JNKmediated β-catenin signaling, which is essential for cordycepin-induced TK-10 cell apoptosis. Our findings are consistent with a recent
report showing that ERK downregulation may
induce cancer apoptosis and that the ERK/
DUSP5/JNK signaling pathway is involved in
TK-10 cell apoptosis after cordycepin treatment. These results indicate that ERK-mediated
JNK negative regulation of β-catenin may be
Akt-dependent. Thus, ERK-mediated negative
regulation of β-catenin by JNK should be considered as a potential therapeutic target.

of β-catenin nuclear translocation by modulating ERK-JNK signaling suggest that cordycepin
has potential as a new drug that could suppress the growth of renal-cancer cells.

Taken together, the pro-apoptotic function and
unique capability of negative regulation by JNK
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